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Prevalence of Bloom Syndrome Heterozygotes
among Ashkenazi Jews
To the Editor:
Bloom syndrome (MIM 210900) is a condition of in-
trauterine and postnatal growth failure, facial erythema,
immunodeficiency, and early malignancies (German
1995). Death from malignancy typically occurs in the
second or third decade (German 1997). At the cellular
level, mutations in both alleles of the Bloom syndrome
gene (BLM) lead to chromosomal breakage, an excess
number of somatic mutations, and an observed increase
in the frequency of sister chromatid exchange in cultured
cells (German et al. 1996). Among 28 of 29 Ashkenazi
Jewish individuals, a single, noncomplementing muta-
tion has been observed (Ellis et al. 1995). This was
shown to be a deletion of 6 bp, followed by insertion
of 7 bp, leading to a frameshift with premature termi-
nation of the encoded gene product (Ellis et al. 1995).
The finding of linkage disequilibrium of this mutation
with neighboring DNA markers demonstrated that this
unusual mutation had a single genetic origin in the Ash-
kenazi Jewish population ∼400–500 years ago (Ellis et
al. 1994). A 1977 survey of Israeli patients with Bloom
syndrome suggested that 1 in 110 Ashkenazi Jews was
a heterozygote for a mutated BLM gene (German et al.
1977).
A number of autosomal recessive conditions are
known to occur with increased frequency among Ash-
kenazi Jews, including Tay-Sachs disease, cystic fibrosis,
Gaucher disease, Canavan disease, Fanconi anemia com-
plementation group C, Niemann-Pick disease, familial
dysautonomia, and Bloom syndrome (Motulsky 1995).
Early success of Tay-Sachs carrier-screening programs
has led to increased interest in screening for other prev-
alent disorders, and as the genetic basis for these con-
ditions is identified, the new information is used to de-
velop carrier-screening tests (Eng et al. 1997; Kronn et
al. 1998). The recent identification of the gene for Bloom
syndrome provided an opportunity to determine the fre-
quency of heterozygotes in the Ashkenazi Jewish pop-
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ulation and thus the practicality of offering heterozygote
testing for this condition (Ellis et al. 1995).
The present study was undertaken to determine the
frequency of the BLM 6bp del/7bp ins mutation
(BLMAsh) in a group of Ashkenazi Jews, unselected for
personal or family history of Bloom syndrome. Patient
samples were collected as part of a carrier-screening pro-
gram for Tay-Sachs, Gaucher, and Canavan diseases and
cystic fibrosis. Eastern European Jewish ancestry was
confirmed by the subjects prior to enrollment in the test-
ing program. They also filled out a questionnaire check-
ing for a family history of genetic diseases, including
Bloom syndrome, and none of the patients included in
this study indicated any family history of Bloom syn-
drome. As required by New York State law, patients
provided written informed consent for the tests that they
requested. In addition, they provided written consent
indicating their willingness to participate in a research
program to determine the frequency of other disease-
susceptibility genes, for which the identity of their DNA
samples would be kept anonymous. This protocol was
approved by the institutional board of research associ-
ates at New York University Medical Center.
To design primers that would enable the amplification
of the region of interest from genomic DNA, we am-
plified the upstream intron for subsequent automated
DNA sequencing by using the Gene Walker Kit (Clon-
tech). A sense primer in the intron between exons 9 and
10 (5′-CCACCACGCCCTGCCTGAGTTATGCTTA-3′)
and an antisense primer in exon 10 (5′-TCTGGA-
GTGACATATAGAAGTTTTATGATTGGGTCTTTTT-
3′) were designed, to amplify a 305-bp fragment encom-
passing the mutation site. The identity of the amplified
fragment was confirmed by DNA sequencing (Genbank
cDNA sequence accession number U39817), and the se-
quence of the BLMAsh mutation was similarly confirmed
by use of the control cell lines GM03403 and GM09960
(National Institute of General Medical Science [NIGMS]
Human Genetic Mutant Cell Repository).
Genomic DNA was extracted by standard techniques.
The region flanking the BLMAsh mutation was amplified
by PCR by means of a hot-start procedure performed
with a Hybaid Omnigene themocycler with the follow-
ing cycle conditions: 1 min at 94C, 1 min at 55C, and
1 min at 72C for 35 cycles, with an additional extension
at 72C for 10 minutes. Mutations were then screened
by Southern blot analysis of the amplified fragment and
chemiluminescent detection (ECL Kit, Amersham) of the
mutant and wild-type alleles with the following allele-
specific oligonucleotide probes: mutant probe: 5′-ACAT-
TAGATTCCAGGT-3′, wild-type probe: 5′-TACATATC-
TGACAGGT-3′.
The mutation was observed in 5 of 1,155 individuals,
yielding a frequency of 1/231 (95% CI 1/123–1/1848).
The confidence interval suggests that the previously es-
timated frequency for heterozygotes in the Israeli Ash-
kenazi Jewish population may have been slightly high
and is consistent with an absence of heterozygote ad-
vantage for carriers of one copy of the mutant allele
(German et al. 1996). The frequency of heterozygotes
for other autosomal recessive conditions within our
panel, including Tay-Sachs (1/28); cystic fibrosis (1/25);
Gaucher disease (1/15); the BRCA2 mutant allele,
6174delT (1/106); Canavan disease (1/41); and Fanconi
anemia complementation group C (1/116; authors’ un-
published data), have been validated in other studies,
suggesting that the test panel is representative of the
Ashkenazi Jewish population (Abeliovich et al. 1992,
1996; Beutler et al. 1993; Kaback et al. 1993; Verlander
et al. 1995; Eng et al. 1997; Kronn et al. 1998). Just as
for these other mutant alleles, we believe that genetic
drift is a sufficient explanation to account for the fre-
quency of the BLMAsh mutation in this population group.
Tay-Sachs disease carrier testing is the paradigm for
genetic screening in the Ashkenazi Jewish population. It
has been widely accepted, with nearly 1 million people
tested worldwide as of 1992 (Kaback et al. 1993). In
recent years, people participating in carrier-screening
programs have elected to undergo screening for cystic
fibrosis and Gaucher disease as well as for Tay-Sachs
disease (Eng et al. 1997; Kronn et al. 1998). Recent
availability of testing for Canavan disease, a severe neu-
rodegenerative disorder, has led to inclusion of this con-
dition in heterozygote screening programs (Kronn et al.
1995). In these screening programs, patient interest in
specific tests has paralleled disease morbidity more
closely than carrier frequency, with screening for the
most prevalent disease (Gaucher disease: 1/15) chosen
the least frequently (Eng et al. 1997; Kronn et al. 1998).
Consistent with its high morbidity and the ability of
mutational analysis to identify a high proportion of car-
riers in the Ashkenazi population (97%), the American
College of Obstetricians and Gynecologists (1998) rec-
ommended carrier screening be offered, ideally, prior to
conception to all Ashkenazi couples on a voluntary basis
with proper informed consent, despite its lower carrier
frequency (1/41). Mutational analysis for Bloom syn-
drome meets many of the previously defined criteria of
Tay-Sachs disease heterozygote-detection programs (Ka-
back et al. 1977) and could be used for screening in this
population, despite the fact that the carrier frequency is
one-fifth that of Canavan disease. The availability of
multiplex genetic screening could contain costs and thus
lead to inclusion of Bloom syndrome in heterozygote
screening programs for Ashkenazi Jews.
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Optimal Ascertainment Strategies to Detect Linkage
to Common Disease Alleles
To the Editor:
The genetic dissection of complex diseases is of great
current interest. The complexity of the task has led to
serious discussion regarding competing strategies for
data collection and analysis. In a previous issue of the
Journal, Badner et al. (1998) contended that extended
densely affected pedigrees (multiplex pedigrees with
many affected individuals) are of little benefit for detec-
tion of linkage to complex traits such as bipolar disorder
(a common psychiatric disorder of complex etiology).
They state that such pedigrees are no more powerful
than nuclear families when the susceptibility allele is
common, and there may be loss of power in the collec-
tion of pedigrees with many affected individuals. Hence,
they voice concern over pedigrees collected by others for
linkage analysis of bipolar disorder (Egeland et al. 1987;
Baron et al. 1994). However, there is merit to a broader
perspective on this important problem.
